News
Today, NIIMBL (the National Institute for Innovation in Manufacturing Biopharmaceuticals) announced that a NIIMBL-led team will receive $10.5 Million in funding through the Gates Grand Challenges Program to advance exceptionally low-cost monoclonal antibody (mAb) manufacturing. Over the three-year award, key partners including Sartorius, Rensselaer...